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Abstract.  We used a series of COOH-terminaUy 
deleted recombinant myosin molecules to map pre- 
cisely the binding sites of 22 monoclonal antibodies 
along the taft of Acanthamoeba myosin-II. These anti- 
bodies bind to 14 distinguishable epitopes, some sepa- 
rated by <10 amino acids. The positions of the bind- 
ing sites visualized by electron microscopy agree only 
approximately with the physical positions of these sites 
on the alpha-helical coiled-coil tail.  On the other 
hand, the epitope map agrees precisely with competi- 
tive binding studies: all antibodies that share an epi- 
tope compete with each other for binding to myosin. 
Antibodies with adjacent epitopes can compete with 
each other at linear distances up to 5 or 6 nm, and 
many antibodies that bind 3-7-nm apart can enhance 
the binding of each other to myosin. Most of the anti- 
bodies that bind to the distal 37 nm of the taft disrupt 
assembly of octameric rninifilaments and, depending 
upon the exact location of the binding site, stop as- 
sembly at specific steps yielding, for example, 
monomers, antiparallel dimers, parallel dimers or an- 
tiparallel tetramers. The effects of these antibodies on 
assembly identify sites on the tail that are required for 
individual steps in minifilament assembly. Experiments 
on the assembly of truncated myosin-II tails have re- 
vealed a complementary group of sites that participate 
in the assembly reactions (Sinard, J. H., D.  L. Rimm, 
and T. D. Pollard.  1990.  J.  Cell Biol.  111:2417- 
2426).  Antibodies that bind to the distal tail but 
do not affect assembly appear to have a low affinity 
for myosin-II. Antibodies that bind to the proximal 50 
nm of the tail do not inhibit the assembly of minifila- 
ments. Many antibodies that bind to the tail of 
myosin-H, even some that have no obvious effect on 
rninifflament assembly, can inhibit the actomyosin 
ATPase activity and the contraction of an actin gel 
formed in crude extracts. An antibody that binds be- 
tween amino acids 1447  and 1467 inhibits the phos- 
phorylation of serine residues distal to residue 1483. 
M 
ONOCLONAL antibodies have been valuable probes 
of myosin structure and function (Kiehart et al., 
1984a,b;  Kiehart and Pollard,  1984a,b;  Peltz et 
al., 1985; Flicker et al., 1985; Winkelman and Lowey, 1986; 
Pagh and Gerisch, 1986; Citi et al., 1989; Trybus 1989; Try- 
bus and Henry, 1989), but the full potential of this approach 
has been limited by the lack of precision in the localization 
of the antibody binding sites along the polypeptide chain. To 
overcome this limitation we used recombinant fusion pro- 
teins with a series of 47 different deletions from the COOH 
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terminus of Acanthamoeba myosin-H to map the binding 
sites of  22 monoclonal antibodies on the tail of  the molecule. 
Similar studies of recombinant fragments from the proximal 
part of the tail established the locations of five other mono- 
clonal antibody binding  sites  (Rimm et al.,  1989). When 
combined with the effects of  these antibodies on minifilament 
assembly, ATPase activity, and gel contraction, the locations 
of the epitopes have defined a number of functionally impor- 
tant parts of the tail. 
Acanthamoeba myosin-H is favorable for such an analysis 
of structure and function, because so much is already known 
about the molecule. It has two heads at one end of a tail 87 
nm long and is composed of two 172-kD heavy chains and 
four light chains (Maruta and Kern,  1977; Pollard  et ai., 
1978; Hammer et al., 1987). It has many properties in com- 
mon with other cytoplasmic myosins (reviewed by Warrick 
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1990).  Its  actin-activated  ATPase activity  is regulated  by 
phosphorylation of the heavy chain (Collins and Korn, 1980) 
near the tip of the tail  (Cot6 et al.,  1984;  Hammer et al., 
1987), but the mechanism of this regulation is not yet under- 
stood.  Myosin-l/assembles  into bipolar  minifilaments  by 
three rapid dimerization  steps  (Sinard et al.,  1989;  Sinard 
and Pollard,  1990). 
The antibodies used in this study come from an extensive 
collection of monoclonal antibodies to Acanthamoeba myo- 
sin-l/ (Kiehart et al.,  1984a). Initial characterization of 23 
of these monoclonal antibodies included a rough localization 
of some of the epitopes by electron microscopy and peptide 
mapping (Kiehart et al.,  1984a,b) as well as an analysis  of 
the effect of each on the assembly, actomyosin ATPase activ- 
ity, and contractility (Kiehart et al., 1984b; Kiehart and Pol- 
lard,  1984a,b).  At low resolution the effects  on function 
could be correlated  with general  regions of the molecule 
such as the head, head-tall junction, or distal part of the tall, 
but the subtle differences  could not be explained  by effects 
on specific  parts of the primary structure. 
Materials and Methods 
Production and Characterization  of 
Monocional Antibodies 
The isolation, purification,  and characterization of 23 monoclonal antibod- 
ies to myosin-H were described by Kiehart et al. (1984a,b).  An additional 
27 antibodies were produced in the same way. These antibodies are named 
M2.x where x is 1 through 50. Briefly, mice were immunized and boosted 
with 200 ~tg of native myosin-IL Hybridoma cells secreting antibody detect- 
able by a solid phase binding assay were cloned twice and grown as ascites 
tumors in mice. For ELISA solid phase binding assays and immunoblotfing, 
antibodies were obtained from cell culture medium without further pu- 
rification.  For myosin ATPase, gel contraction, electron microscopy, anti- 
body isotyping, and antibody isoelectric  focusing, antibodies were purified 
from ascites fluid by low ionic strength precipitation (for IgMs) or ion ex- 
change chromatography (for lgGs) according  to Kiehart et al.  (1984a, 
1986). For competitive binding assays radioactive antibodies were labeled 
biosynthetically  with [aSS]methionine or chemically with 1231 (Kiehart et 
al.,  1984a,  1986).  Purified  antibodies were used as cold competitors in 
competitive  binding assays. 
Isolation and Expression of the Myosin-ll Tail 
Fragment cDNA Clone 
The cDNA clone 3.9.3 encodes the COOH-terminal 567 amino acids of 
myosin-H, the stop codon, the 3' untranslated region, and the poly A tail 
(Rimm et al.,  1989). Clone 3.9.3 was subcloued into two different expres- 
sion vectors, pATH-I1 and pRX-1 (Rimm and Pollard,  1989). Fusion pro- 
reins purilled from Escherichia coli transformed  with either vector form 
bipolar minifilaments  (Sinard et al.,  1990),  shewing that the recombinant 
tail is similar to native myosin-H tail. 
Construction of the COOH-Terminal Deletion Studies 
The 3.9.3 clone was subcloned into Bluescript (Stratagene,  La Jolla, CA) 
and its orientation was determined by restriction mapping. The plasmid was 
then lmearized with Hind Ill, a restriction enzyme that cuts adjacent to the 
3' end of the 3.9.3 insert. The linearized plasmid was divided into aliqoots 
and digested with the exonuclease Bal 31 (Promege Biotec, Madison, Wl) 
as described in Maniatis et al. (1982) for 9 or 15 min at room temperature. 
The ends left by the exonuclease  were polished with Klenow polymerase 
and ligeted to Xba I multiple frame stop codon linkers (Pharmacia Fine 
Chemicals, Piscataway, NJ). The ligated  DNA was digested with Eco RI 
and Xba I for 2 h at 370C, electmphoresed on 1% agerose gels, and the ap- 
propriate sized smear of DNA fragments was cut out of the gel and electro- 
eluted.  These fragments were subcloned into Eco RI/Xba t-cut pATH-11s 
plasmid, a defi~tive of  the pATH-11 plasmid described below. The ligations 
were transformed into E.  coli strain HB101 and screened for inserts by 
colony hybridization (Maniatis et ai., 1982). There were 150 colonies with 
deleted  3.9.3  cDNA inserted.  Plasmid minipreps (Holmes and Quigley, 
1981) were done on colonies with inserts and the resultant DNA was restric- 
tion mapped and the 3' ends of the inserts were sequenced  (Sanger et al., 
1977) using a synthetic primer complementary to a region just 3' to the in- 
sertion site of pATH-11s. All of the fusion proteins consist of 37 kD of tryp- 
tophan synthetase followed by 31 amino acids coded by linker DNA and 
then myosin-II amino acids beginning at residue 942. We named each clone 
after its carboxy-terminal  amino acid. Myosin-II consists of 1,509 residues 
with the COOH terminus at the tip of the tail (Hammer et al.,  1987). 
Construction of the Expression Vector,  pATH-11s 
The plasmid expression vector used is a derivative of pATH-11, a vector 
used successfully  for expression  of this clone in previous work (Rimm et 
al.,  1989). The derivative,  pATH-Ils,  was made to insure that the newly 
deleted 3' ends would contain a minimum of linker-ceded amino acids by 
insertion of a stop codon in all three reading frames.  This was achieved by 
cutting pATH-11 DNA at its only Xba I site, filling in the ends with Klenew 
polymerase and ligating to Xba I multiple frame stop codons as described 
above. They were then recut with Xba I, electrophoresed to remove unincor- 
porated linkers, and relignted. The resultant vectors were transformed into 
I-IB101 and sequenced to confirm the insertion of the multiple frame stop 
fragment. 
Expression of  Recombinant Myosin Fragments 
The clones were grown, induced, and harvested as described in detail else- 
where (Rimm and PoBard,  1989). Briefly, cells are diluted from stationary 
phase in 3-5 vol of M9+CA medium and grown 3 h at 30°C, induced with 
10 mM indolyl acrylic acid, and grown three more hours.  Gel samples are 
made by pelleting 1 ml of a cell suspension for 10 s in a microfuge, washing 
with 1 ml of 10 mM Tris-C1 (pH 7.5), resuspending in 100 ~1 of Laemmli 
(1970) sample buffer, and boiling for 3 rain before loading  I0 tzl on a 7.5% 
SDS-polyacrylamide gel. 
Gel Electrophoresis and Western Blot Technique 
Gel electrophoresis and blotting onto nitrocellulose was done by minor 
modifications  of the methods of Kiehart et al. (1984a).  The nitrocellulose 
filter was removed from the apparatus,  stained with 0.2 % Ponceau S in 3 % 
trichloroacetic acid, blocked in Twuen-BSA buffer (100 mM NaC1, 10 mM 
Tris-C1, pH 7.5, 0.1% Tween 20, 0.005 % thimerosol, 1% bovine serum albu- 
min) and incubated for 1 h at room temperature in a Tween-BSA buffer with 
10 pg/ml of purified  monoclonal antibody or 1:1-1:2 dilution of secreted 
monnelonal antibody in cell culture medium. Afar three washes for 10 rain 
each in Tween buffer without the BSA, the blot was incubated in 10/tg/ml 
peroxidase-linked  goat anti-mouse antibody (HyClone Laboratories, Lo- 
gan,  UT)  or  1  x  105  cpm/ml iodinated goat anti-mouse antibody in 
Tween-BSA buffer. After a  1 h incubation and two Tween buffer washes, 
the blots with peroxidase-linked  antibodies were washed twice with TBS 
buffer (10 mM Tris-C1,  150 mM NaCl) and then developed  using 0.03% 
hydrogen peroxide and 0.6 mg/ml 4 chloro-naphthol  in TBS containing 20% 
methanol for 5-15 rain. If t25I-secund antibody was used, the blots were 
washed three times for 10 minutes each in Tween buffer, air dried, and ex- 
posed overnight in cassettes with Kodak XAR-5  film. 
Other Biochemical Methods 
Myosin-l] was purified according to Sinard and Pollard (1989) and kindly 
provided by Dr. John Sinard of Johns Hopkins Medical School.  Assays for 
the contraction of gelled cytoplasmic extracts and the actomyosin ATPase 
activity were done according to Kiehart and Pollard (19840).  Myosin-II 
heavy chain kinase activity was measured with a partially purified kinase 
and a method described by Cot~ et al. (1981). 
Electron Microscopy 
Samples of myosin-II alone or with monoclonal antibodies were negatively 
stained with 1% uranyl acetate (Pollard,  1982) or mixed with glycerol and 
sprayed onto mica for rotary shadowing (Kiebart et al., 1984b). To test for 
effects of a monoclonal antibody on the assembly of minifllaments,  a 1.3-2- 
fold molar excess of  antibody was mixed with  monomeric my0sin-II in 400 mM 
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the shorter fusion proteins. By this criterion, an epitope was 
located between the end of the smallest fusion protein that 
bound the antibody and the longest fusion protein that did 
not bind the antibody. As thus defined,  the epitopes have a 
mean length of only 12 residues (or 3.5 turns of the helix) 
with a range of  4-28 residues. We realize, of course, that the 
physical binding sites may actually extend into the sequence 
of the longest fusion protein that did not bind the antibody. 
This procedure produced a detailed map of the 14 distin- 
guishable epitopes (Fig.  2).  Note that no monoclonal anti- 
body bound at more than one site and that all antibodies that 
bound denatured  myosin-II on blots  also bound to fusion 
proteins.  Together with three epitopes mapped previously 
near the head (Rimm et al., 1989), we have identified 17 epi- 
Figure I. Immunoblots used to localize the binding site for mono- 
clonal antibodies M2.3, M2.17, M2.31, and M2.33 on bacterial ly- 
sates containing a series of  myosin-II  fusion proteins with deletions 
at the COOH terminus of the heavy chain.  The numbers at the top 
of each gel lane indicate  the last residue present in the fusion pro- 
tein. After PAGE the fusion proteins were transferred  to nitrocellu- 
lose, stained  lightly with amido black, and then reacted with the 
monoclonal antibody. In every case there is a sharp distinction be- 
tween the reaction of the antibody with the pair of fusion proteins 
at the boundary of the epitope. For example M2.3 binds to the fu- 
sion protein terminating at 1,410 but not that terminating at 1,399. 
This establishes  that residues between  1,399 and 1,410 are essential 
for binding this antibody. 
KCI, 3% sucrose, 12 mM imidazole, pH 7 for 1 h on ice and then diluted 
to give final concentrations  of 0.1/~M myosin-H,  0.15% sucrose, 40 mM 
KC1, 10 mM imidazole, pH 7. Under these conditions more than 95% of 
myosin-lI  forms  octameric minifilaments (Sinard and Pollard, 1989). Elec- 
tron micrographs  of  well preserved areas were recorded  and the results tabu- 
lated on prints by an observer uninformed about the nature of the ex- 
perimental manipulations. 
Results 
High Resolution Epitope Mapping of  Monoclonal 
Antibodies That Bind the Tail of  Myosin-II 
We determined the binding sites on the tail of  Acanthamoeba 
myosin-II for 22 different monoclonal antibodies by reacting 
each with a  series of fusion proteins that differed in length 
at their COOH termini (Fig.  1). The fusion proteins in crude 
bacterial lysates were separated by SDS-PAGE and then blot- 
ted onto nitrocellulose,. Representative examples of this pro- 
cedure are shown for four monoclonal antibodies (Fig. 1). In 
every case, the epitope was identified clearly because a given 
antibody reacted with all of the fusion proteins longer than 
Figure 2. Epitope map of the monoclonal antibodies  that bind to 
the tail  of myosin-II. The  scales  on the  left  give the  length  in 
residues  and nanometers from the head tail junction. The horizon- 
tal bars to the right of the tail indicate  the COOH-terminal ends 
of fusion proteins that were used to localize the binding sites  for 
the groups of monoclonal antibodies listed on the far right. In addi- 
tion to the 22 antibodies  mapped distal  to residue  1,178 in this 
study, the figure includes  six additional  antibodies  mapped on the 
proximal  part of the tail by Rimm et al. (1989).  The boxes around 
groups of antibodies  indicate  those that compete with each other 
for binding to myosin-II. 
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Figure 3. Comparison of the position of antibody binding sites on 
the tail of myosin-U  defined  by deletion mapping with the positions 
measured by electron microscopy of shadowed antigen-antibody 
complexes. The vertical bars represent the mean positions from 
electron microscopy ±1  SD.  The horizontal bars represent the 
boundaries of the antibody binding site determined by deletion 
mapping. The numbers of  the antibodies are indicated near the bars. 
topes on the tail. They are distributed from one end to the 
other, but are biased toward the COOH terminal half of the 
tall.  However,  none  have been  identified on  the  last 27 
residues that are presumably not alpha-helical and include 
the three heavy chain pbosphorylation sites (Hammer et al., 
1987).  Single antibodies bind to 10 of these sites.  Two anti- 
bodies bind to each of three of these sites and three antibod- 
ies bind to each of four sites. 
The  sequences of the minimal epitopes  defined by the 
borders of  the deletions do not have any features that strongly 
differentiate them from the rest of the myosin-l] tail. Most 
of these epitopes are hydrophilic according to the criteria of 
Hopp and Woods (1983). 7 of 14 epitopes have a net.negative 
charge, 4 are neutral, and 3 have a net positive charge. Over- 
all the epitopes have a net negative charge of 0.105 per resi- 
due, substantially higher than the tail as a whole which has 
a net negative charge of 0.045  per residue. 
Comparison of Electron Microscopic Localization of 
Binding Sites with Epitope Position 
Since the tail of myosin-II is an alpha-helical coiled-coil, the 
epitope map defines precisely the physical position of each 
antibody binding site and provides an opportunity to evaluate 
the accuracy of antibody localization by electron micros- 
copy. In addition to data reported earlier for M2.1, M2.3, 
M2.4,  M2.9,  M2.10,  M2.12,  and M2.46  (Kiehart et al., 
1984b;  Rimm  et  al.,  1989),  we  have  localized  M2.19, 
M2.22,  M2.23,  M2.28,  M2.31,  M2.33,  M2.36,  M2.3g, 
M2.40, M2.44, M2.47, M2.49, and M2.50 (Fig. 3). Com- 
plexes of some antibodies with myosin-U do not survive the 
drying and shadowing procedure, including M2.5, M2.14, 
M2.15, M2.20, and M2.24. 
The apparent positions of some of the antibody binding 
sites on the tail of myosin-II visualized by electron micros- 
copy of sprayed and shadowed molecules differ from the ac- 
tual epitope positions by up to 30 nm (Fig. 3). In many cases, 
especially near the tip of the tail, electron microscopy un- 
derestimates the distance of the epitope from the head-tall 
junction, but in other cases electron microscopy overesti- 
mates this distance. All antibodies that bind to the last 20 nm 
of the tail obscure the part of the tail distal to the antibody. 
This is true even for M2.50 that binds to residues almost 30 
tun from the end of the helical domain; <10% of these com- 
plexes had tail exposed beyond the antibody. These results 
show the limitations of  relying solely on electron microscopy 
to localize antibody binding sites on the tails of  myosin mole- 
cules, especially for sites near the end of the tail. 
Effect of  Epitope Position on the Ability of 
Monoclonal Antibodies to Compete with Each Other 
for Binding to an Alpha-Helical Coiled-Coil 
There is complete agreement between the high resolution 
epitope map and the results of competitive binding experi- 
ments (Table I and Figs. 2 and 4). Almost all antibodies that 
share a given epitope as demarcated by the method in Fig. 
1, compete with each other for binding to myosin-II (Figs. 
2 and 4) in a solid phase assay. Given the size of the bound- 
aries of these epitopes, the binding sites of competing anti- 
bodies are generally separated by <5 nm (or ,x,10 turns of 
the alpha,helix) along the coiled-coil (Fig. 2). 
Antibodies that bind to different epitopes can either in- 
hibit, enhance or have no effect on the binding of each other 
to myosin-II as  illustrated for test antibodies M2.47  and 
M2.9 in Fig. 4, top and center. Fig. 4, bottom summarizes the 
results of competition between 161 pairs of antibodies with 
epitopes located <13 nm apart. Antibodies that bind >7 nm 
apart do not compete with each other (Fig. 4, bottom and ex- 
tensive data not illustrated). 
Antibodies that are located <7 nm apart on the coiled-coil 
can compete with each other, but this is not obligatory. The 
probability of competition is high below 3 nm (six turns of 
the alpha-helix) and drops off with the distance between the 
epitopes (Fig. 4, bottom). Inhibition of  binding is frequently 
(21 cases), but not always (31 cases) reciprocal, most likely 
depending upon the relative affinities of the two antibodies 
for myosin-H. In the rare cases where antibodies bind close 
together but do not compete, they may simply bind at differ- 
ent azimuthal positions. 
Some antibodies enhance the binding of others to myosin- 
H by 150-300% (Fig. 4, top and center, and other examples 
not illustrated). The highest probability of enhancement oc- 
curs at epitopes separated by 3-7 nm along the tail (Fig. 4, 
bottom). The enhancement is reciprocal in only 4 out of 31 
cases. 
Effects of Tail Binding Monoclonal Antibodies on the 
Assembly of  Myosin-lI 
Having mapped the binding sites of  the library of  tall binding 
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antibodies, we completed an analysis of their effects on the 
assembly of  myosin-II minitilaments that was initiated by Kie- 
hart et at. (1984b). Assembly was analyzed by electron mi- 
croscopy of both negatively stained and rotary-shadowed 
specimens. Rotary shadowing provided much additional in- 
formation not revealed in the earlier study with negative 
staining alone. This analysis was also facilitated by recent 
advances in our understanding of the assembly mechanism 
and  the  demonstration  that  rotary  shadowing  is  a  valid 
method to visualize assembly intermediates present in solu- 
tion (Sinard and Pollard, 1989,  1990; Sinard et at.,  1989). 
The normal pathway of assembly involves three very rapid 
dimerization  steps:  two  monomers  form  an  antiparallel 
dimer  (/G  <10  -~°  M);  two  dimers  form  an  antiparallel 
tetramer  (Kd <10  -1° M);  and  two  tetramers  form an  an- 
tiparallel octamer (K~ =  2  ×  10  -s M) (see Fig. 7, below). 
The effects of the antibodies on the assembly of minifila- 
ments depend on both the position of  the binding site and the 
affinity of the antibody (Table I and Fig. 5). In general, anti- 
bodies that bind to the proximal 50 nm of the tail do not pre- 
vent assembly of minifilaments, while most antibodies that 
bind to the distal 37 nm of  the tail disrupt the normal pathway 
of assembly with a wide variety of consequences. The anti- 
bodies that bind to the distal 37 nm of the tail but fail to in- 
hibit assembly appear to have lower affinity for myosin-l/ 
than  the  antibodies  that  disrupt  assembly.  They will be 
presented separately at the end of this section. 
All antibodies tested that bind to the proximal 50 nm of 
the tail allow assembly of bipolar minitilaments (Fig. 5 for 
M2.38 and M2.46; Kiehart et at.  [1984b]  for M2.1, M2.4, 
and  M2.10).  Those that bind near the head-tail junction 
decorate the ends of the minifilaments (Kiehart et at., 1984b 
for M2.1, M2.4, and M2.10). Those that bind in the middle 
of the tail may decorate the bare zone (Fig. 5 for M2.46), 
but some do not (Fig. 5 for M2.38).  Electron microscopy 
(especially negative staining) does not provide reliable quan- 
titative data on the extent of the assembly reaction, so we 
cannot rule out some inhibition of the assembly process by 
one or more of these antibodies. 
The antibodies that bind tightly to the distal 37 nm of the 
myosin-i/tail can sequester the myosin-i/in the monomeric 
state or allow the assembly of  higher order structures includ- 
ing dimers and tetramers (Fig. 5, Table I). Some of these are 
intermediates  along  the  normal  assembly  pathway,  while 
others are abnormal intermediates arising from the inhibi- 
tion of a preceding step in the pathway.  We will consider 
these antibodies in order of  their binding sites from proximal 
Figure 4. Competition between monoclonal antibodies for binding 
to myosin-II. (/bp) Effects of various antibodies on the binding of 
radiolabeled M2.47 to myosin-H in a solid phase binding assay. A 
large excess of each competing antibody was tested separately. The 
graph illustrates the zones that we have defined as having no effect, 
enhanced binding or inhibition of binding. These definitions are 
used in the summary of results in the bottom panel. (Center) An 
experiment similar to the top panel with M2.29 as the labeled anti- 
body. (Bottom) A plot of the frequency of inhibition, no effect, and 
enhancementof  antibody binding as a function of the physical dis- 
tances defined by deletion mapping between the binding sites of  the 
labeled antibody and each test antibody. 
Rimm et al. Myosin-ll  Monoclonal Antibodies  2409 Table L Monoclonal Antibodies to the Tail of  Acanthamoeba Myosin-ll 
Antibody  Competitive binding  Epitope  location  Effect  on  Effect  on actin-  Effect on  Effect on  Effect on 
name  Isotype  group  (deletion analysis) CaATPase activated  MgATPase  gel contraction  polymerization  phosphorylation 
M2.1  IgG2A  M2.1  942-999  No effect  Inhibits  Inhibits  No effect 
M2.3  IgG2B  M2.3,8,33,40,47  1400-1405  No effect  Inhibits  Inhibits  1>4>2"  No effect 
M2.4  IgG2B  M2.4,6,10  881-942  No effect  Inhibits  Inhibits  No effect 
M2.6  IgG2B  M2.4,6,10  881-942  No effect  Inhibits  Inhibits  No effect 
M2.8  IgM  M2.3,8,33,40,47  1400-1405  No effect  Inhibits 
M2.9  IgG1  M2.9,31  1333-1340  No effect  Inhibits  Inhibits  8>4>I>2 
M2.10  IgG1  M2.4,6,10  881-942  No effect  Inhibits  Inhibits  No effect 
M2.12  IgG2B  M2.12,23,28,29,(8)  1419-1429  No effect  Inhibits  Inhibits  1>4>2"  No effect 
M2.14  IgG1  M2.14,15  1191-1218 
M2.15  IgG1  M2.14,15  1191-1218  No effect  No effect  Inhibits  No effect 
M2.19  IgG1  M2.19  1264-1274  No effect  Inhibits  Inhibits weakly  8>16>4,  1 
M2.22  IgG1  M2.22  942-999  No effect  No effect  No effect  No effect 
M2.23  IgG2B  M2.12,23,28,29,(8)  1419-1429  No effect  No effect  Inhibits  No effect 
M2.28  IgG2B  M2.12,23,28,29,(8)  1419-1429  No effect  No effect  Inhibits  1>2>4"  No effect 
M2.29  M2.12,23,28,29,44,45,49  1430-1436 
M2.31  IgG2B  M2.9,31  1352-1360  No effect  No effect  Inhibits  8>4>2>1 
M2.32  M2.32  1468-1481 
M2.33  IgG1  M2.3,8,33,40,47  1391-1394  No effect  Inhibits  Inhibits  1>2>8>, 4* 
M2.36  IgG2B  M2.36,39,50  1236-1259  No effect  No effect  Inhibits  1>2>4" 
M2.38  IgGl  M2.38  1179-1185  No effect  Inhibits weakly 
M2.39  IgM  M2.36,39,50  1281-1297  No effect 
M2.40  IgG2B  M2.3,8,33,40',47  1391-1394  No effect  No effect  8>4>1 
M2.44  IgG2B  M2.29,44,45,49  1448-1467  No effect  Inhibits weakly  Inhibits  1  Inhibits ,030% 
M2.45  IgO2B  M2.29,44,45,49  1448-1467  No effect  No effect 
M2.46  IgG2B  M2.46  1048-1102  No effect  Inhibits weakly  Inhibits  8>16>4>1" 
M2.47  IgOl  M2.3,8,33,40,47  1401)-1405  No effect  Inhibits  Inhibits  8, 4>1>2 
M2.49  IgG2B  M2.29,44,45,49  1448-1467  No effect  Inhibits weakly  1>2>4" 
M2.50  IgG1  M2.36,39,50  1275-1280  No effect  No effect  Inhibits weakly  8>4>16,  1>2" 
Summary of the properties including isotype, competitive  binding groups, binding sites, and effects on ATPase activities, gel contraction, polymerization, and 
phosphorylation of the heavy chain. The results of polymerization  experiments are summarized by listing the size of the products in order of frequency with 
1 ffi monomer, 2 = dimer, 4 = tetramer, and 8 ffi octamer. An asterix (*) indicates that the antibody remained bound to the myosin  after shadowing. Blank calls, 
not tested. 
to distal. In each case we note the binding site as a distance 
from the head-tall junction. 
When assessed by negative staining, M2.36 (binding at 52 
nm) appeared to allow the assembly of tiny filaments and to 
decorate the bare zone, but after spraying and shadowing, 
decorated monomers and antiparallel dimers were the major 
species (Fig. 5). This antibody may simply destabilize any 
filaments that form to an extent where they do not survive 
spraying and shadowing. 
M2.50 (57 nm) inhibits the formation of octamers from 
antiparallel  tetramers  (Fig.  5).  Compared  with  controls 
where  octamers  predominate,  in  the  presence  of M2.50 
nearly half of the myosin-l/molecules are in the form of 
tetramers  with  normal  bare  zone  geometry.  All  of the 
tetramers and octamers have two or more antibodies bound 
to the bare zone. 
M2.19  (55  nm) does not inhibit assembly and does not 
decorate  the  minifilaments  (Fig.  5).  In high  salt  <5 %  of 
monomers have an M2.19 bound after shadowing, a further 
indication of low affinity. 
M2.33 binds ,,o73 nm from the head-tail junction and in- 
hibits assembly. Most of the myosin-l/is monomeric or ag- 
gregated  in  clusters  without  defined  geometry,  but a  few 
dimers and tetramers are also present (Fig.  5). 
M2.3 and M2.47 bind to the same epitope (defined by de- 
letions at residues 1,399 and 1,405) 75 nm from the head-tail 
junction but have different effects on assembly.  M2.3  par- 
tially inhibits the formation of dimers as well as the higher 
order assembly of these dimers (Fig. 5). This yields predom- 
inantly monomers along with a  substantial  number of an- 
tiparallel dimers. Most of the dimers and monomers have an- 
tibody bound near the tip of the taft (Fig. 5).  Many of the 
"tetramers"  may  be  myosin-l/  molecules  cross-linked  by 
bivalent antibodies near the tips of their tails.  No filaments 
are present in negatively stained  specimens.  On the other 
hand, M2.47 partially inhibits assembly at the tetramer step 
and  leaves  a  few  monomers.  Neither  the  tetramers  or 
monomers  have  M2.47  bound,  at  least  after  drying  and 
shadowing (Fig. 5). Short filaments (perhaps tetramers) are 
present in negatively stained specimens. 
M2.12 and M2.28 bind between residues  1,418 and 1,429 
,~78  nm  from the  head-tail  junction,  Although  negative 
staining revealed some filaments  in the presence of M2.12 
(Kiehart et al.,  1984b and confirmed by new experiments), 
there  are  very  few  complete  minifilaments  after  rotary 
shadowing  (Fig.  5).  Instead there  was  a  mixture  of bare 
monomers, monomers with an antibody bound near the tip 
of the tail and a few tetramers.  In the presence of M2.28 no 
filaments were observed by either method.  The specimens 
were similar in appearance to those with M2.12 except for 
the presence of a few parallel dimers with a stagger of '~,15 
nm and an antibody bound near the tip of the tail. 
The Journal of Cell Biology, Volume 111, 1990  2410 Figure 5. Effects of monoclonal antibodies on the assembly of myosin-II minifilaments assessed by electron microscopy of sprayed and 
shadowed specimens. The electron micrographs were selected to illustrate the range of structures present in each specimen. The histograms 
give the frequency distributions of  myosin-II oligomers formed in the presence of  each monoclonal antibody. Monomers, dimers, tetramers, 
octamers, and hexadecamers are indicated by different shading with the size of the major species indicated above its bar in each graph. 
The antibody numbers are indicated on each histogram.  Bar, 100 nm. 
Both M2.44 and M2.49 (84 nm) prevent the formation of 
filaments detectable by negative staining. With M2.44 only 
monomers are present in rotary shadowed specimens (Fig. 
5). M2.49 produces an interesting mixture of  monomers and 
parallel dimers (Fig. 5). The two molecules in these dimers 
are staggered by ~15 nm with the two tails bound together 
at a site ~60 nm from its head-tail junction of the leading 
molecule and ~45 nm from the heads of the trailing mole- 
cule. In these parallel dimers the trailing molecule usually 
has an antibody bound at the tip of its tail. M2.32 binds to 
the most distal epitope on the tail, 85 nm from the head-tail 
junction, and strongly inhibits assembly (not illustrated). 
Several antibodies that bind to the distal part of  the tail fail 
to inhibit assembly even when their epitopes are near those 
of an inhibitory antibody. For example, M2.33 and M2.40 
both bind between residues 1,391 and 1,394, but only M2.33 
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Figure 6. Effects of lO-fold molar excess concentrations  of moao- 
clonal antibodies on the time course of  myosin-II  heavy chain phos- 
phorylation. A background of 423 cpm was subtracted from each 
specimen. (n) antibody buffer; (,x) M2.23; (e) M2.28; (o) Alice; 
(I) M2.44. 
has an obvious effect on assembly yielding predominantly 
monomers (Fig. 5). One clear difference between these two 
antibodies  is that M2.33  remains bound to  many of the 
monomers and dimers while M2.40 does not bind to any of 
the products of assembly. Similarly M2.19 (55 nm) does not 
inhibit assembly and does not decorate the mini  filaments 
(Fig.  5).  In high salt <5%  of monomers have an M2.19 
bound after shadowing, a further indication of low affinity. 
Effects of  Monoclonal Antibodies on 
Actomyosin ATPase Activity and Contraction of 
Gelled Cytoplasmic Extracts 
Many of the monoclonal antibodies that bind to the tail of 
myosin-II inhibit the actin-activated Mg~+-ATPase and the 
contraction of gelled cytoplasmic extracts (see Table I for a 
summary  of  all  antibodies  tested;  Kiehart  and  Pollard, 
1984a,b  for original data on M2.1,  M2.3,  M2.4,  M2.6, 
M2.9,  M2.10,  M2.15,  and M2.19).  The contraction assay 
was done with high speed supernatants of sucrose extracts 
of Acanthamoeba cytoplasm that form a gel when warmed to 
room temperature and that then undergo an ATP-dependent 
contraction. The ATPase assay was done with dephosphory- 
lated myosin-II in 7 mM MgCI2, which causes the lateral 
aggregation of fully formed octameric minifilaments but not 
of tetramers or smaller assembly intermediates (Sinard and 
Pollard,  1989). 
All of  the antibodies tested (M2.3, M2.12, M2.28, M2.33, 
M2.36,  and  M2.44)  that held myosin-II in  the  form of 
monomers  or  rimers  under  polymerizing conditions in- 
hibited either or both the actin-activated Mg~+ATPase activ- 
ity and the contraction of gelled extracts (Table I). Antibody 
M2.31, which has ambiguous effects on assembly, inhibited 
both functional assays. These extensive results are consistent 
with our previous conclusion that soluble complexes of mo- 
homeric myosin-II with antibody have low ATPase activity 
and cannot generate the force required to contract gelled ex- 
tracts  (Kiehart and Pollard,  1984a,b).  These results also 
agree with the inhibition of both assembly and actomyosin 
ATPase activity by proteolytic removal of the COOH-termi- 
nal 66 amino acids from the tail of myosin-II (Kuznicki et 
al.,  1985) and by polyclonal antipeptide antibodies to resi- 
dues 1,463-1,481  (Atkinson et al.,  1988). 
The three antibodies that produce mixtures of tetramer 
and octamers, M2.9, M2.47, and M2.50, gave slightly differ- 
ent results. M2.9 and M2.47 inhibited both the actomyosin 
ATPase and contraction, while M2.50 inhibited contraction 
some, but not all of the time. Tentatively, we conclude that 
tetramers have low ATPase activity and are ineffective in the 
gel contraction assay, but this deserves closer scrutiny in the 
future. 
The  antibodies that bind  to  the  proximal part  (M2.4, 
M2.6, M2.10) or the middle (M2.15,  M2.19, and M2.46) of 
the tail and do not prevent assembly of  minifilaments  can still 
interfere with both the actomyosin ATPase activity and gel 
contraction (Table D. Thus, inhibition of polymerization is 
not the only mechanism that accounts for loss of these ac- 
tivities. 
Effect of  Monoclonal Antibodies on Phosphorylation 
of the Myosin-II Heavy Chain 
Although none of  the 50 monoclonal antibodies bound to the 
nonhelical region at the tip of the tail where the three phos- 
phorylated serines are located (Cot~ et al., 1984), one anti- 
body, M2.44 that binds between residues  1447  and 1467, 
partially inhibited phosphorylation of the heavy chain (Fig. 
6). In the presence of this antibody both the rate and extent 
of the phosphorylation were reduced by about one-third. 
Neither M2.23 nor M2.28, two antibodies that bind to an ad- 
jacent epitope between residues 1,418 and 1,429, inhibited 
the kinase. 
Discussion 
Comparison of  Epitope Mapping Methods 
Our characterization of 25 monoclonal antibodies that bind 
to the tail of myosin-II provides new insights about the ac- 
curacy  and  resolution of four different epitope  mapping 
methods. Mapping on a deletion series prepared by expres- 
sion of recombinant fusion proteins clearly has the highest 
resolution and accuracy, at least for linear epitopes like those 
characterized here. The method can easily and unambigu- 
ously  define  the  edge  of epitopes  to  a  few  amino  acid 
residues. The resolution is limited only by the effort invested 
in the isolation of  a collection of  deleted cDNAs. Others have 
shown that mapping on two deletion series, one from each 
end of a protein, does not improve the resolution (Gross and 
Rohrmann, 1990). The deletion map confirmed our previous 
groupings of antibodies by peptide mapping (Kiehart et al., 
1984a).  Epitope  mapping  on  peptides  was  correct  but 
limited in resolution by the size of the peptides and knowl- 
edge about their positions along the polypeptide chain. 
Competitive binding experiments also provide very reli- 
able data on the proximity of antibodies with neighboring 
epitopes along a linear structure (Fig. 4).  Antibodies that 
bind close together have a high probability of inhibiting the 
binding of each other to the myosin tail. This probability 
falls to zero for epitopes with center to center spacing >6.2 
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mechanism of this inhibition is most likely steric hindrance 
between the antibodies bound to the myosin. Therefore, ob- 
servation of inhibition in a competitive binding assay estab- 
lishes that the two antibodies bind within 6.2 nm on a coiled- 
coil.  On the other hand, a  negative result cannot exclude 
binding even with 3 nm. Jackson et al. (1988) demonstrated 
that two monoclonal antibodies can bind simultaneously to 
two epitopes separated by only three amino acids. 
Electron microscopy of antibody/antigen  complexes on the 
tail of myosin-II has provided rough estimates of the epitope 
locations, but it has two limitations for high resolution epi- 
tope mapping that are unrelated to the resolution of the mi- 
croscope. First, a large fraction of the antibody/antigen  com- 
plexes do not survive preparation for electron microscopy. 
Second, some antibodies appear to bind as much as 30 nm 
away from their epitopes defined by deletion mapping. This 
problem is minimal near the heads but is severe near the end 
of the myosin tall. Many antibodies that bind within 30 nm 
of the COOH terminus appear to be localized at the tip of 
the tail and in most cases the tail appears to be foreshort- 
ened. Binding of the antibody somehow obscures or distorts 
the distal part of the tail. 
Characterization of  Epitopes 
The combined results of deletion mapping and competitive 
binding assays lead to the conclusion that few residues con- 
tribute to high affinity binding of antibodies to the tail of 
myosin-II, but that the region of antigen-antibody contact is 
likely to be extensive. Many monoclonal antibodies show a 
profound difference in binding to two fusion proteins differ- 
ing in length at their COOH termini by <10 amino acids (1.5 
nm or three turns of the alpha-helix) (Fig. 2). In one case 
such a difference was observed with the deletion of only four 
residues (Fig. 2). Our immunoblot assay is not quantitative, 
but we expect that positive and negative results (Fig. 1) repre- 
sent differences of orders of magnitude in the binding con- 
stants. On the other hand, the competitive binding experi- 
ments (Fig. 4) show that the linear extent of  the tail in contact 
with each antibody is much greater than 1.5 nm, since the 
probability of competition between two monoclonal antibod- 
ies is high when they bind to adjacent sites <5 nm apart. 
Given the width of a  coiled-coil (2 nm), contact sites are 
likely to be on the order of 10 nm  2. This is about the same 
size as the 7-8 nm  2 contacts between lysozyme and three 
different monoclonal antibodies that have been studied at 
atomic resolution (see Davies et al.,  1988). 
Although we have resolved 17 different epitopes on the tail 
of myosin-II and although 2 or more independently derived 
monoclonal antibodies bind to 7 of these sites, we doubt that 
we have identified all of the antigenic sites on the tall. First, 
we continued to find new epitopes in each new group of 
monoclonal antibodies tested. Second, the tail is structurally 
homogeneous and the side chain chemistry of the known epi- 
topes does not distinguish them from the other parts of the 
tail with no known epitope. This leads us to favor the conclu- 
sion of Benjamin et al. (1984) that the whole exposed surface 
is potentially antigenic. 
Further definition of the epitopes circumscribed by the de- 
letion map might be obtained by testing the effect of amino 
acid substitutions on antibody binding or by testing a panel 
of synthetic peptides overlapping the epitope for their ability 
to inhibit antibody binding (see for example, Schoofs et al., 
1988; Tan et al., 1990). Substitution of amino acids in fusion 
proteins by in vitro mutagenesis or  in synthetic peptides 
might provide information about the azimuthal orientations 
of the epitopes. On the other hand, detailed studies of lyso- 
zyme have established that there is no simple, quantitative 
relationship between variations in  amino acid  side  chain 
chemistry of an antigen and antibody affinity (reviewed by 
Davies et al., 1988),  so more insight about most of the epi- 
topes described here would require x-ray crystallography of 
the antigen-antibody complex. 
Enhancement 
Our competitive binding experiments provide a new insight 
into the process by which one monoclonal antibody can en- 
hance the binding of another antibody to an antigen. Such 
enhancement has been observed many times with both pro- 
tein (Ehrlich et al., 1982;  Holmes and Parham, 1983) and 
polysaccharide (Greenspan et al.,  1987) antigens, but there 
has never been a detailed assessment of the role of epitope 
proximity on the probability of enhancement. Since the epi- 
topes on the tail of myosin-II are present in a stereotyped, 
linear array, and since we tested a large collection of antibod- 
ies, we learned that enhancement is most likely when two 
epitopes are separated by 3-7 nm (Fig. 4). 
This  new  information is  consistent  with  two  different 
mechanisms that have been suggested for enhancement, both 
of which require local effects. (We think that we can rule out 
formation of cyclic antigen-antibody complexes as invoked 
for other systems [Ehrlich et al., 1982],  since our antigen is 
immobilized on a surface.) The first local mechanism is that 
the enhancing antibody alters the conformation of the anti- 
gen and increases the affinity of a neighboring epitope for its 
antibody. This has been suggested for systems where Fab 
fragments of immunoglobulins enhance the binding of other 
monoclonal antibodies (Heinz et al.,  1984;  Parham et al., 
1986).  In support of this mechanism, x-ray crystallography 
has  revealed  small  changes  in  the  structure  of lysozyme 
bound to an antibody (see Davies et al., 1988).  One would 
expect that antibody-induced conformational change in a 
coiled-coil to propagate over a  limited distance, and this 
could explain the limited zone of enhancement adjacent to 
any epitope. The second local mechanism is that the Fc do- 
mains of one antibody might interact with an antibody bound 
to an adjacent site and enhance its binding to the antigen. 
This has been suggested in cases where intact antibodies are 
more effective enhancers than Fab's  (Ehrlich et al.,  1982; 
Greenspan et al.,  1987).  Such a mechanism would require 
adjacent epitopes as we observed. Our results cannot distin- 
guish these two alternatives (or some trivial explanation for 
enhancement), but do define for the first time the linear dis- 
tance over which such enhanced binding can occur. 
Identification of Sites on the Myosin-II Tail That Are 
Critical for Minifilament Assembly 
Antibody affinity appears to be particularly important in the 
effects of antibodies on myosin-II assembly, since the myosin- 
II molecules have such a high affinity for each other (Sinard 
and Pollard, 1990).  This may lead to a situation where an 
antibody binds to a site essential for polymerization but fails 
to inhibit assembly since it has a lower affinity for myosin-II 
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M2.47 are examples of antibodies that bind to the same site 
but differ in affinity. By both electron microscopy and immu- 
noblotting M2.3 appears to have a much higher affinity for 
the tail than M2.47 and is a much stronger inhibitor of as- 
sembly. M2.33 (strong) and M2.40 (weak) are another ex- 
ample of this behavior. It is probably not coincidental that 
all  of the  antibodies  (M2.9,  M2.19,  M2.31,  M2.40,  and 
M2.47) that inhibit assembly poorly, compared with anti- 
bodies on the same or adjacent sites, do not bind to myosin-II 
in shadowed specimens. On the other hand, antibodies that 
strongly inhibit one or more steps are nearly always visible 
on the blocked intermediates after shadowing (Fig. 5). 
Since the minifilaments are held together by specific inter- 
actions between the tails of the myosin-II molecules, the 
effects of a monoclonal antibody depend on several geomet- 
rical factors, including the size of the antibody and the lon- 
gitudinal and azimuthal position of the epitope.  Although 
only a few amino acids contribute to high affinity binding, 
the region of the myosin-II tall covered by the antibody is 
substantially larger, ~5 nm long. Thus antibody binding can 
sterically block interactions that occur over a relatively large 
area,  ~10 mn  2. The longitudinal location is obviously im- 
portant for interfering with molecular associations. The sen- 
sitivity to azimuthal position was not anticipated because we 
thought that a bulky antibody bound to the slender tall of 
myosin-II might block interactions in all directions. How- 
ever, given that antigens bind in a shallow groove on one end 
of the Fab domain (Davies et al.,  1988;  Stanfield et al., 
1990),  at least part of the coiled-coil is likely to be exposed 
even at the antibody binding site.  Such exposed surfaces of 
the  tail can apparently participate  in binding  to  another 
myosin-II molecule. If the azimuthal positions of the epi- 
topes were known, it might be possible to deduce the pack- 
ing of the tails in the minifilaments. 
With one exception, the effects of the monoclonal antibod- 
ies on assembly can be explained by steric hindrance of the 
associations required for one or more of the three dimeriza- 
tion reactions required to form minifilaments (Fig. 7). The 
figure illustrates our interpretation of all of the results, so 
only the main points are discussed in the following para- 
graphs. For each antibody we have included the most abun- 
dant species.  In several cases,  we also show second most 
abundant  species,  when  its  structure  is  revealing  of the 
mechanism of assembly. When viewing this figure, keep in 
mind that it is drawn in two dimensions, since nothing is 
known about the packing of the tails in the third dimension. 
The effects of these IgGs are remarkably discrete with clear 
differences apparent even between two antibodies that bind 
to the same epitope. We have not compared these effects of 
IgGs with the effects of Fab fragments of these antibodies, 
but expect that even more subtle differences will be revealed 
by the smaller probes. 
Figure 7. Diagramatic summary of the effects  of monoclonal anti- 
bodies on the assembly of myosin-II minifilaments. This scale 
drawing with the antibodies precisely positioned at their binding 
sites illustrates one or two major species of oligomers formed in 
the presence of each antibody. Two different antibody shapes are 
used to illustrate the different azimuthal positions postulated to ac- 
count for the observed assembly intermediates. The normal assem- 
bly pathway is illustrated at the top. Note that two different antibod- 
ies such as M2.44 and M2.12,  M2.49 and M2.28,  and M2.3 and 
M2.33 can give the same products even though they bind to differ- 
ent sites. 
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lows step 2 to a limited extent. Since these two antibodies 
bind to the same epitope, the difference is likely to be due 
to the azimuthal positions of the epitopes, with M2.49 leav- 
ing open laterally a site required for the parallel association 
of the last 15 nm of coiled-coil with the second 15 nm of the 
trailing myosin-II molecule. Both blocked sites are required 
for step 3. 
The pair, M2.12 and M2.28, have effects that closely par- 
allel those of M2.44 and M2.49,  even though the M2.12/ 
M2.28 epitope is at least 20 residues closer to the head than 
the M2.44 epitope. The formation of these parallel dimers 
in the presence of M2.49 and M2.28 shows that the second 
assembly step is not absolutely dependent upon prior forma- 
tion of antiparallel dimers. This conclusion is confirmed by 
experiments with myosin-lI fusion proteins (Sinard et al., 
1990).  Molecules lacking the tail piece cannot form anti- 
parallel dimers (step  1) but can still make parallel dimers 
staggered by 15 nm (step 2). 
M2.3 and M2.33 bind to adjacent epitopes and have simi- 
lar effects on assembly. Both completely inhibit steps 2 and 
3 but only partially inhibit step  1.  Both epitopes are just 
COOH-terminal to the site at residue 1,380 postulated by 
Sinard et al. (1989) to be the initial binding site on the coiled- 
coil for the nonhelical tail piece during step 1, so these anti- 
bodies must bind in an azimuthal position that does not block 
the binding site. 
M2.50 binds outside the region of 15 nm overlap in an- 
tiparallel dimers and allows steps 1 and 2 but not step 3. The 
antibody binds within the overlap used in step 2.  Since at 
least two different  intermolecular interactions are required to 
bind together two antiparallel dimers, we cannot argue per- 
suasively that the azimuthal position fortuitously allows both 
of these interactions as illustrated in Fig. 7. Rather, we sus- 
pect that the essential associations for step 2 are largely or 
entirely in a  narrow  ,,o20 nm zone in the middle of the 
tetramer. The importance of this central region is supported 
by the formation of myosin-II fusion protein tetramers and 
octamers that are held together only near the tips of their 
tails (see Fig. 7 in Sinard et al., 1990).  Associations outside 
the central region required for step 3 are blocked by M2.50. 
The effect of M2.36 on assembly provides the only exam- 
pie that cannot be explained simply by steric hindrance. This 
antibody binds outside the regions of the distal tail that over- 
lap in steps  1 and 2 and yet it inhibits both of these steps. 
Therefore, it must have some long range effect that remains 
mysterious. It might be related to the fact that M2.36 binds 
near proline 1,244 where the tail frequently bends (Hammer 
et al.,  1988). 
The results with monoclonal antibodies complement our 
analysis of the assembly of myosin-II fusion proteins with 
COOH-terminal deletions (Sinard et al., 1990). The COOH- 
terminal deletions have identified three very short sequences 
in the last 15 nm of the tail that are essential for each of the 
three steps (see Figs. 1 and 13 in Sinard et al., 1990).  Con- 
sidering these to be donor sites, there must be acceptor sites 
on adjacent myosin-II molecules in minifilaments. The anti- 
bodies have been particularly useful for identifying  these ac- 
ceptor sites (Fig. 7), because the binding properties of these 
acceptor sites cannot be tested by reconstitution for two rea- 
sons.  First, neither the donor nor acceptor sites are self- 
sufficient for  assembly,  and  second,  there  are  extensive 
regions of interaction and no individual residues are likely 
to contribute much binding energy. In addition, the antibod- 
ies have revealed one site where they may exert long-range 
effects on the conformation of essential binding sites. 
Identification of  a Site on the Coiled-Coil that 
Affects Phosphorylation 
M2.44 binds to an epitope defined by residues 1,44%1,46% 
near the end of the coiled-coil at 1481 and inhibits by one 
third phosphorylation in the nonhelical COOH-terminal do- 
main. We speculate that this represents nearly complete inhi- 
bition of phosphorylation at one of three serines located at 
positions 1,484,  1,489, and 1,494 (Cot~ et al.,  1984).  This 
antibody binds 1%37 residues (3-5 nm) away from the prox- 
imal phosphorylation site.  At this distance ,,o30% of anti- 
bodies inhibit binding of a neighboring antibody (Fig. 4), so 
the most likely mechanism of  inhibition of  the kinase is steric 
hindrance of enzyme binding to its substrate.  Other less 
likely possibilities include the folding back of the nonhelical 
tail piece onto the helical part of the tail to make direct con- 
tact with the M2.44 epitope or that the heavy chain kinase 
has a recognition site that extends into the helical region of 
the tail. 
Comparison with Previous Work 
Monoclonal antibodies have probably not reached their full 
potential for revealing how myosin assembles and functions, 
because our results and each of the earlier studies have all 
provided unique insights. For example, there are antibodies 
to vertebrate myosin-II that can stabilize filaments (Trybus 
and Henry, 1989),  stabilize folded monomers or extended 
monomers (Citi et al., 1989), or inhibit assembly (Citi et al., 
1989). All of these antibodies were useful in elucidating the 
relationships among conformation, assembly, phosphoryla- 
tion,  and  ATPase  activity.  Antibodies  to  Dictyostelium 
myosin-lI have a wide range of effects on assembly, motility, 
and  actin-activated ATPase  activity  (Peltz  et  al.,  1985; 
Flicker et al., 1985; Pagh and Gerisch, 1986). These results 
generally parallel our results with Acanthamoeba myosin-H 
in establishing the importance of the distal tail in assembly 
and of assembly on enzyme activity. One of these monoclo- 
nal antibodies to Dictyostelium myosin-II even inhibited an- 
tiparallel associations but not parallel associations of the 
tails (Pagh and Gerisch, 1986),  an effect similar to M2.49 
and M2.28. When the precise location of these epitopes and 
the details of the Dictyostelium myosin-II assembly mecha- 
nism become available,  it will be interesting to see whether 
there are any general principles governing the assembly and 
functions of these two myosin-IIs that differ considerably in 
the length of their tails. 
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